These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 11576692)

  • 1. The drug efflux-metabolism alliance: biochemical aspects.
    Benet LZ; Cummins CL
    Adv Drug Deliv Rev; 2001 Oct; 50 Suppl 1():S3-11. PubMed ID: 11576692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein.
    Zhang Y; Benet LZ
    Clin Pharmacokinet; 2001; 40(3):159-68. PubMed ID: 11327196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of human CYP3A and P-glycoprotein on the absorption of drugs.
    van de Waterbeemd H
    Eur J Pharm Sci; 2000 Nov; 12(1):1. PubMed ID: 11121728
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine.
    Suzuki H; Sugiyama Y
    Eur J Pharm Sci; 2000 Nov; 12(1):3-12. PubMed ID: 11121729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transport proteins and intestinal metabolism: P-glycoprotein and cytochrome P4503A.
    Christians U
    Ther Drug Monit; 2004 Apr; 26(2):104-6. PubMed ID: 15228147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.
    Patel J; Mitra AK
    Pharmacogenomics; 2001 Nov; 2(4):401-15. PubMed ID: 11722289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
    Raeissi SD; Hidalgo IJ; Segura-Aguilar J; Artursson P
    Pharm Res; 1999 May; 16(5):625-32. PubMed ID: 10350002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Grapefruit juice activates P-glycoprotein-mediated drug transport.
    Soldner A; Christians U; Susanto M; Wacher VJ; Silverman JA; Benet LZ
    Pharm Res; 1999 Apr; 16(4):478-85. PubMed ID: 10227700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mdr1 limits CYP3A metabolism in vivo.
    Lan LB; Dalton JT; Schuetz EG
    Mol Pharmacol; 2000 Oct; 58(4):863-9. PubMed ID: 10999959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
    Kim RB; Wandel C; Leake B; Cvetkovic M; Fromm MF; Dempsey PJ; Roden MM; Belas F; Chaudhary AK; Roden DM; Wood AJ; Wilkinson GR
    Pharm Res; 1999 Mar; 16(3):408-14. PubMed ID: 10213372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active secretion and enterocytic drug metabolism barriers to drug absorption.
    Wacher VJ; Salphati L; Benet LZ
    Adv Drug Deliv Rev; 2001 Mar; 46(1-3):89-102. PubMed ID: 11259835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-Glycoprotein in clinical cardiology.
    Rodriguez I; Abernethy DR; Woosley RL
    Circulation; 1999 Feb; 99(4):472-4. PubMed ID: 9927391
    [No Abstract]   [Full Text] [Related]  

  • 13. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics.
    Wacher VJ; Silverman JA; Zhang Y; Benet LZ
    J Pharm Sci; 1998 Nov; 87(11):1322-30. PubMed ID: 9811484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.
    Wacher VJ; Wu CY; Benet LZ
    Mol Carcinog; 1995 Jul; 13(3):129-34. PubMed ID: 7619215
    [No Abstract]   [Full Text] [Related]  

  • 16. Can oral midazolam predict oral cyclosporine disposition?
    Paine MF; Davis CL; Shen DD; Marsh CL; Raisys VA; Thummel KE
    Eur J Pharm Sci; 2000 Nov; 12(1):51-62. PubMed ID: 11121733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.
    Wilkinson GR
    J Pharmacokinet Biopharm; 1996 Oct; 24(5):475-90. PubMed ID: 9131486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative bioavailability of Neoral versus Sandimmune in the presence of a P450IIIA and P-glycoprotein inhibitor.
    Choc MG; Mueller EA; Robinson WT; Kumle A; Smith HT; Charnick SB
    Transplant Proc; 1998 Aug; 30(5):1664-5. PubMed ID: 9723234
    [No Abstract]   [Full Text] [Related]  

  • 19. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data.
    Benet LZ; Cummins CL; Wu CY
    Curr Drug Metab; 2003 Oct; 4(5):393-8. PubMed ID: 14529371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein.
    Evans DC; O'Connor D; Lake BG; Evers R; Allen C; Hargreaves R
    Drug Metab Dispos; 2003 Jul; 31(7):861-9. PubMed ID: 12814962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.